https://www.thebodypro.com/category/tipranavir-aptivus

Tipranavir (Aptivus)

The Latest

News

New Pediatric Dosing for Aptivus, Patients 2-18 Years, New Oral Solution and Info on Coadministration With Midazolam

On June 23, 2008, FDA approved a new Aptivus (tipranavir) oral solution (100 mg/mL). The product label has been updated to include dosing recommendations for pediatric patients 2-18 years of age. In addition, information regarding oral and parentera...

Conference Coverage

New Data on Tipranavir Highlight the Agent's Benefits

Approximately two years have passed since the initial approval of tipranavir (TPV, Aptivus), yet our knowledge of this agent continues to grow through ongoing research. New findings presented at the 4th International AIDS Society Conference on HIV Pa...

Conference Coverage

Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time

Tipranavir (TPV, Aptivus) is a non-peptidic, new-generation protease inhibitor (PI) that has proven to be potent against HIV-1 isolates resistant to all other available PIs. Combined results from the phase III tipranavir trials RESIST-1, conducted in...

Conference Coverage

Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies

There is a pressing need for additional drugs to manage individuals who have developed resistance to currently available antiretroviral agents. Several new protease inhibitors (PIs) have recently been developed and approved in the United States for t...

Conference Coverage

Ritonavir-Boosted Tipranavir More Effective Than Other Ritonavir-Boosted PIs in HIV-Infected Patients With PI Resistance

This was a fairly large, clinic-based, retrospective analysis1 of virologic response rates to a broad range of ritonavir (RTV, Norvir)-boosted protease inhibitors (PIs), including saquinavir (SQV, Invirase) 1,000 mg twice daily, indinavir (IDV, Crixi...

Conference Coverage

Use of Tipranavir for Patients With Little Prior PI Experience

Tipranavir (TPV, Aptivus) is a novel protease inhibitor (PI) with potent activity against HIV that is resistant to multiple PIs. Its efficacy has been evaluated in two large phase 3 trials called RESIST (Randomized Evaluation of Strategic Interventio...

Study of Tipranavir for First-Line Treatment Ends Early

Ingelheim/Germany -- Boehringer Ingelheim is actively conducting a clinical trial program to further evaluate Aptivus® (tipranavir) capsules for the treatment of HIV-1 infection. The program is comprised of ongoing and planned studies in more than 1,...

Tipranavir Update at CROI 2006: RESIST Study Results, Drug Interactions and Therapeutic Drug Monitoring

Background There are many HIV-infected patients who have multi-drug resistant virus and/or medication intolerances and thus are faced with limited treatment options. Tipranavir (TPV, Aptivus) was approved in June 2005 for patients in need of new ant...

Tipranavir Heralds New Era for Treatment-Experienced Patients, Recent Studies Attest

Tipranavir (TPV, Aptivus) is the newest protease inhibitor (PI) to become available in the United States (and soon enough in other parts of the world) having been approved June 22, 2005. As previously reported, it's a non-peptidic PI that has a disti...

News

FDA Approval of Aptivus (Tipranavir)

On June 22, 2005, the US Food and Drug Administration (FDA) granted accelerated approval of Aptivus (tipranavir), a protease inhibitor. Aptivus, co-administered with 200 mg of ritonavir, is indicated for use as part of combination antiretroviral trea...